Sugi Predict

Sugi Predict / Compounds / SCHEMBL3753571

SCHEMBL3753571

SCHEMBL3753571

CC(C)(C)OC(=O)N1CCN(c2cc(F)cc(Br)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ PDK2 Q15119 1/20 0.47
▸ GPR119 Q8TDV5 7/20 0.45
▸ BACE1 P56817 2/20 0.44
▸ ESRRB O95718 1/20 0.44
▸ ESR1 P03372 1/20 0.44
▸ ESRRA P11474 1/20 0.44
▸ ESRRG P62508 1/20 0.44
▸ NAMPT P43490 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ ABCB1 P08183 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4941538 0.90 MAPT (0.56) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL24847031 0.90 MAPT (0.56) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL30930919 0.85 MAPT (0.51) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL20708147 0.85 GPR119 (0.53) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL19001559 0.85 MAPT (0.51) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL5341377 0.85 PHGDH (0.48) MAPTALDH1A1LMNAPDK2GPR119
Piperazine SCHEMBL27197226 0.84 MAPT (0.50) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL31036793 0.84 MAPT (0.50) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL31623073 0.84 MAPT (0.52) MAPTALDH1A1LMNAPDK2GPR119
SCHEMBL18277892 0.84 MAPT (0.50) MAPTALDH1A1LMNAPDK2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035367-A1 PKC-Theta Modulators CELGENE CORPORATION (US) 2026-02-05 — — US disclosed
US-20240383868-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-11-21 — — US disclosed
US-20240262821-A1 PKC-Theta Modulators EXSCIENTIA AL LIMITED (GB) 2024-08-08 — — US disclosed
EP-4333982-A1 PKC-THETA MODULATORS Exscientia Al Limited (GB) 2024-03-13 — — EP disclosed
CN-117355522-A PKC-theta modulators 爱智药人工智能有限公司 2024-01-05 — — CN disclosed
EP-4294790-A1 SMARCA DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-12-27 — — EP disclosed
WO-2022234298-A1 PKC-THETA MODULATORS EXSCIENTIA AI LIMITED (GB) 2022-11-10 — — WO disclosed
WO-2022178532-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-08-25 — — WO disclosed
EP-3209664-B1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-06-03 — — EP disclosed
EP-2770994-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2019-08-21 — — EP disclosed
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-05 — — US disclosed
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-05 — — US disclosed
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2013-09-05 — — US disclosed
WO-2013051672-A1 MEDICINAL AGENT COMPRISING THIAZOLIDINE DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT 株式会社ヤクルト本社 (JP) 2013-04-11 — — WO disclosed
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2010-11-25 — — US disclosed
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2010-11-25 — — US disclosed
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2010-11-25 — — US disclosed
EP-2200436-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS The Scripps Research Institute (US) 2010-06-30 — — EP disclosed
WO-2009032861-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-03-12 — — WO disclosed
WO-2009032861-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035367-A1 PKC-Theta Modulators PRKAR2B, PRKAR2A, PRKCD MAPT 3317/4885ALDH1A1 4459/4885LMNA 1615/4885
US-20130231336-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 MAPT 1055/4885ALDH1A1 4097/4885LMNA 3037/4885
US-20100298312-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K5, MAP3K7 MAPT 1055/4885ALDH1A1 4097/4885LMNA 3037/4885
US-20240262821-A1 PKC-Theta Modulators PRKCQ, PRKCH, PRKCE MAPT 1623/4885ALDH1A1 4352/4885LMNA 1418/4885
US-20240383868-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 MAPT 3823/4885ALDH1A1 2230/4885LMNA 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.